beta
Trial Radar AI
Clinical Trial NCT06856278 for Anaplastic Throid Carcinoma is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC Phase 1, Phase 2 30 Monoclonal Antibody

Not yet recruiting
Clinical Trial NCT06856278 is designed to study Treatment for Anaplastic Throid Carcinoma. This Phase 1 Phase 2 interventional study is not yet recruiting. Enrollment is planned to begin on February 22, 2025 until the study accrues 30 participants. Led by Zhejiang Provincial People's Hospital, this study is expected to complete by March 1, 2029. The latest data from ClinicalTrials.gov was last updated on March 4, 2025.
Brief Summary
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Official Title

Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)

Conditions
Anaplastic Throid Carcinoma
Other Study IDs
  • CAR-NK GeT
NCT ID Number
NCT06856278
Start Date (Actual)
2025-02-22
Last Update Posted
2025-03-04
Completion Date (Estimated)
2029-03-01
Enrollment (Estimated)
30
Study Type
Interventional
PHASE
Phase 1
Phase 2
Status
Not yet recruiting
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Experimentaltreated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
NKG2D CAR-NK with PD-1 Antibody
Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Safety and tolerability
Safety and tolerability at 28 days after combination therapy, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) were determined.
From the start of the trial to day 56 after the first infusion of CAR-NK.
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. Age 18-75 years (including boundary values), male or female.
  2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.
  3. Liver and kidney function is good, and can tolerate treatment.
  4. Be able to cooperate with the completion of treatment and follow-up work.
  5. No other systemic diseases, including other malignancies.

  1. Need to breastfeed the baby or have fertility needs；
  2. Immune system diseases;
  3. Diseases of the blood system;
  4. Mental system diseases;
  5. Interstitial pneumonia, lung disease, etc.;
  6. Failure to follow rules of this study.
Zhejiang Provincial People's Hospital logoZhejiang Provincial People's Hospital
Study Central Contact
Contact: Minghua Ge, +86-0571 87666666, [email protected]
1 Study Locations in 1 Countries

Zhejiang

Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China